The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.
This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,490 trial records at the last sync on 25 Sep 2026, 03:16 UTC; this register shows the 2,500 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.
This page shows the 15 of those trials with a site in Parkinson’s disease.
15 of the 2,500 most recently authorised trials in this register list a site in Parkinson’s disease; 2 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.
| Phase | Trials | Share |
|---|---|---|
| Phase II | 7 | 46.7% |
| Phase I | 6 | 40% |
| Phase III | 2 | 13.3% |
| Lead sponsor | Trials |
|---|---|
| Tridem Bioscience FlexCo | 2 |
| Amsterdam UMC Stichting | 1 |
| Askbio Inc. | 1 |
| Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret A.S. | 1 |
| H. Lundbeck A/S | 1 |
| Helse Bergen HF | 1 |
| Karolinska Institutet | 1 |
| Karolinska University Hospital | 1 |
| Mission Therapeutics Limited | 1 |
| Regeneron Pharmaceuticals Inc. | 1 |